a study to evaluate the safety and tolerability of ro7296682 in combination with atezolizumab in participants with advanced solid tumors.

Conditions: Solid Tumors

Summary: this study will evaluate the safety, tolerability and preliminary anti-tumor activity of ro7296682 in combination with atezolizumab in participants with advanced solid tumors.


Eligibility criteria:
inclusion criteria: - diagnosis of advanced and/or metastatic solid tumors who have progressed on a standard therapy, are intolerant to standard of care (soc), and/or and non-amenable to soc. participants whose tumors have known sensitizing mutations must have experienced disease progression (during or after treatment) or intolerance to treatment with a respective targeted therapy. * measurable disease according to recist v1.1. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * able to provide the most recent archival tumor tissue samples. * adequate cardiovascular, haematological, liver and renal function. * participants on therapeutic anticoagulation must be on a stable anticoagulant regimen. * women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods. * men: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods and refrain from donating sperm. exclusion criteria: * pregnancy, lactation, or breastfeeding. * known hypersensitivity to any of the components of ro7296682 and atezolizumab, including but not limited to hypersensitivity to chinese hamster ovary cell products or other recombinant human or humanized antibodies. * history or clinical evidence of central nervous system (cns) primary tumors or metastases. * participants with another invasive malignancy in the last two years. * participants with known active or uncontrolled infection. * positive hiv test at screening. * positive for hepatitis b and c. * vaccination with live vaccines within 28 days prior to c1d1. * major surgical procedure or significant traumatic injury within 28 days prior to first ro7296682 and atezolizumab infusion. * participants with wound healing complications. * dementia or altered mental status that would prohibit informed consent. * history of stevens-johnson syndrome, toxic epidermal necrolysis, or dress (drug rash with eosinophilia and systemic symptoms). * active or history of autoimmune disease or immune deficiency. * prior treatment with cpis (e.g. anti-ctla4, anti-pd1, anti-pdl1), immunomodulatory monoclonal antibodies (mabs) and/or mab-derived therapies (approved or investigational) is approved. * treatment with standard radiotherapy, any chemotherapeutic agent, targeted therapy or treatment with any other investigational drug (defined as treatment for which there is currently no regulatory authority-approved indication) within 28 days or 5 half-lives of the drug (whichever is shorter), prior to the first ro7296882 administration on c1d1. * radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy (for which no wash out period is required).

Keywords: rg6292